1843 related articles for article (PubMed ID: 27550197)
1. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
[TBL] [Abstract][Full Text] [Related]
2. mRNA expressions of androgen receptor and its variants in matched hormone-sensitive and castration-resistant prostate cancer.
Park HK; Lim SD; Kwon GY
Scand J Urol; 2019 Dec; 53(6):365-371. PubMed ID: 31809622
[No Abstract] [Full Text] [Related]
3. Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer.
Welti J; Rodrigues DN; Sharp A; Sun S; Lorente D; Riisnaes R; Figueiredo I; Zafeiriou Z; Rescigno P; de Bono JS; Plymate SR
Eur Urol; 2016 Oct; 70(4):599-608. PubMed ID: 27117751
[TBL] [Abstract][Full Text] [Related]
4. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.
Hu R; Lu C; Mostaghel EA; Yegnasubramanian S; Gurel M; Tannahill C; Edwards J; Isaacs WB; Nelson PS; Bluemn E; Plymate SR; Luo J
Cancer Res; 2012 Jul; 72(14):3457-62. PubMed ID: 22710436
[TBL] [Abstract][Full Text] [Related]
5. Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance.
Kohli M; Ho Y; Hillman DW; Van Etten JL; Henzler C; Yang R; Sperger JM; Li Y; Tseng E; Hon T; Clark T; Tan W; Carlson RE; Wang L; Sicotte H; Thai H; Jimenez R; Huang H; Vedell PT; Eckloff BW; Quevedo JF; Pitot HC; Costello BA; Jen J; Wieben ED; Silverstein KAT; Lang JM; Wang L; Dehm SM
Clin Cancer Res; 2017 Aug; 23(16):4704-4715. PubMed ID: 28473535
[No Abstract] [Full Text] [Related]
6. Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer.
Sharp A; Coleman I; Yuan W; Sprenger C; Dolling D; Rodrigues DN; Russo JW; Figueiredo I; Bertan C; Seed G; Riisnaes R; Uo T; Neeb A; Welti J; Morrissey C; Carreira S; Luo J; Nelson PS; Balk SP; True LD; de Bono JS; Plymate SR
J Clin Invest; 2019 Jan; 129(1):192-208. PubMed ID: 30334814
[TBL] [Abstract][Full Text] [Related]
7. Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model.
Nakata D; Nakayama K; Masaki T; Tanaka A; Kusaka M; Watanabe T
Prostate; 2016 Dec; 76(16):1536-1545. PubMed ID: 27473672
[TBL] [Abstract][Full Text] [Related]
8. Bruceantin targets HSP90 to overcome resistance to hormone therapy in castration-resistant prostate cancer.
Moon SJ; Jeong BC; Kim HJ; Lim JE; Kim HJ; Kwon GY; Jackman JA; Kim JH
Theranostics; 2021; 11(2):958-973. PubMed ID: 33391515
[No Abstract] [Full Text] [Related]
9. High-Content Screening Identifies Src Family Kinases as Potential Regulators of AR-V7 Expression and Androgen-Independent Cell Growth.
Szafran AT; Stephan C; Bolt M; Mancini MG; Marcelli M; Mancini MA
Prostate; 2017 Jan; 77(1):82-93. PubMed ID: 27699828
[TBL] [Abstract][Full Text] [Related]
10. Standardization of CTC AR-V7 PCR assay and evaluation of its role in castration resistant prostate cancer progression.
Tommasi S; Pilato B; Carella C; Lasorella A; Danza K; Vallini I; De Summa S; Naglieri E
Prostate; 2019 Jan; 79(1):54-61. PubMed ID: 30141201
[TBL] [Abstract][Full Text] [Related]
11. CX4945 suppresses the growth of castration-resistant prostate cancer cells by reducing AR-V7 expression.
Deng C; Chen J; Guo S; Wang Y; Zhou Q; Li Z; Yang X; Yu X; Zhang Z; Zhou F; Han H; Yao K
World J Urol; 2017 Aug; 35(8):1213-1221. PubMed ID: 28105499
[TBL] [Abstract][Full Text] [Related]
12. Differential expression of androgen receptor variants in hormone-sensitive prostate cancer xenografts, castration-resistant sublines, and patient specimens according to the treatment sequence.
Honda M; Kimura T; Kamata Y; Tashiro K; Kimura S; Koike Y; Sato S; Yorozu T; Furusato B; Takahashi H; Kiyota H; Egawa S
Prostate; 2019 Jun; 79(9):1043-1052. PubMed ID: 30998834
[TBL] [Abstract][Full Text] [Related]
13. Melatonin Inhibits Androgen Receptor Splice Variant-7 (AR-V7)-Induced Nuclear Factor-Kappa B (NF-κB) Activation and NF-κB Activator-Induced AR-V7 Expression in Prostate Cancer Cells: Potential Implications for the Use of Melatonin in Castration-Resistant Prostate Cancer (CRPC) Therapy.
Liu VWS; Yau WL; Tam CW; Yao KM; Shiu SYW
Int J Mol Sci; 2017 May; 18(6):. PubMed ID: 28561752
[TBL] [Abstract][Full Text] [Related]
14. Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13.
Chen Z; Wu D; Thomas-Ahner JM; Lu C; Zhao P; Zhang Q; Geraghty C; Yan PS; Hankey W; Sunkel B; Cheng X; Antonarakis ES; Wang QE; Liu Z; Huang TH; Jin VX; Clinton SK; Luo J; Huang J; Wang Q
Proc Natl Acad Sci U S A; 2018 Jun; 115(26):6810-6815. PubMed ID: 29844167
[TBL] [Abstract][Full Text] [Related]
15. Transcription of Nrdp1 by the androgen receptor is regulated by nuclear filamin A in prostate cancer.
Savoy RM; Chen L; Siddiqui S; Melgoza FU; Durbin-Johnson B; Drake C; Jathal MK; Bose S; Steele TM; Mooso BA; D'Abronzo LS; Fry WH; Carraway KL; Mudryj M; Ghosh PM
Endocr Relat Cancer; 2015 Jun; 22(3):369-86. PubMed ID: 25759396
[TBL] [Abstract][Full Text] [Related]
16. Multimodal actions of the phytochemical sulforaphane suppress both AR and AR-V7 in 22Rv1 cells: Advocating a potent pharmaceutical combination against castration-resistant prostate cancer.
Khurana N; Kim H; Chandra PK; Talwar S; Sharma P; Abdel-Mageed AB; Sikka SC; Mondal D
Oncol Rep; 2017 Nov; 38(5):2774-2786. PubMed ID: 28901514
[TBL] [Abstract][Full Text] [Related]
17. Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer.
Cao Q; Song Z; Ruan H; Wang C; Yang X; Bao L; Wang K; Cheng G; Xu T; Xiao W; Xiong Z; Liu D; Yang M; Zhou D; Yang H; Chen K; Zhang X
Clin Cancer Res; 2020 Mar; 26(6):1516-1528. PubMed ID: 31796514
[TBL] [Abstract][Full Text] [Related]
18. Suppression of prostate tumor cell survival by antisense oligonucleotide-mediated inhibition of AR-V7 mRNA synthesis.
Luna Velez MV; Verhaegh GW; Smit F; Sedelaar JPM; Schalken JA
Oncogene; 2019 May; 38(19):3696-3709. PubMed ID: 30664691
[TBL] [Abstract][Full Text] [Related]
19. High levels of the AR-V7 Splice Variant and Co-Amplification of the Golgi Protein Coding YIPF6 in AR Amplified Prostate Cancer Bone Metastases.
Djusberg E; Jernberg E; Thysell E; Golovleva I; Lundberg P; Crnalic S; Widmark A; Bergh A; Brattsand M; Wikström P
Prostate; 2017 May; 77(6):625-638. PubMed ID: 28144969
[TBL] [Abstract][Full Text] [Related]
20. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
